-
-
-
-
-
-
-
Apnimed prices IPO at $16 per share, raising $192 million
-
-
-
-
-
-
-
Jones Trading on Capricor Therapeutics (CAPR): 'this is the first time we have seen the magnitude of difference in primary outcome'
-
-
-
-
-
-
-
Arcus and Summit team up to test kidney cancer drug combo
-
-
-
-
-
-
-
Scholar Rock says apitegromab EU approval delayed by facility review
-
-
-
-
-
-
-
Wells Fargo Starts Pharvaris B.V. (PHVS) at Overweight
-
-
-
-
-
-
-
Goldman Sachs Starts Praxis Precision Medicines Inc. (PRAX) at Buy
-
-
-
-
-
-
-
FDA accepts Pharvaris NDA for oral HAE attack treatment deucrictibant
-
15,615 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

